Fig. 1: Development of Secondary Myeloid Neoplasia (SMN) After CAR-T Cell Therapy. | Bone Marrow Transplantation

Fig. 1: Development of Secondary Myeloid Neoplasia (SMN) After CAR-T Cell Therapy.

From: Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study

Fig. 1

a Cumulative incidence of secondary myeloid neoplasms (SMN) following CAR-T therapy across 16 Italian centers. b Overall survival curve for patients with SMNs. The median overall survival was 10.4 months (95% CI 2.6–11.3), based on Kaplan–Meier analysis. c Mutations detected in 11 patients (79%) tested for clonal hematopoiesis at MDS onset. The Median Variant allele frequency (VAF, %) is displayed on the side.

Back to article page